Cognetivity Neurosciences Ltd
Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Co… Read more
Cognetivity Neurosciences Ltd (CGNSF) - Net Assets
Latest net assets as of October 2023: $-15.20 Million USD
Based on the latest financial reports, Cognetivity Neurosciences Ltd (CGNSF) has net assets worth $-15.20 Million USD as of October 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($486.61K) and total liabilities ($15.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-15.20 Million |
| % of Total Assets | -3122.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | -2162.86% |
| 10-Year Change | N/A |
| Growth Volatility | 301.76 |
Cognetivity Neurosciences Ltd - Net Assets Trend (2016–2023)
This chart illustrates how Cognetivity Neurosciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cognetivity Neurosciences Ltd (2016–2023)
The table below shows the annual net assets of Cognetivity Neurosciences Ltd from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-01-31 | $-9.89 Million | -74.25% |
| 2022-01-31 | $-5.68 Million | -757.70% |
| 2021-01-31 | $862.91K | +428.06% |
| 2020-01-31 | $-263.04K | -154.87% |
| 2019-01-31 | $479.41K | -85.85% |
| 2018-01-31 | $3.39 Million | +3507.78% |
| 2017-01-31 | $-99.43K | +18.85% |
| 2016-01-31 | $-122.52K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cognetivity Neurosciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3127614100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.67 Million | % |
| Other Comprehensive Income | $5.84 Million | % |
| Other Components | $1.00 | % |
| Total Equity | $-9.89 Million | 100.00% |
Cognetivity Neurosciences Ltd Competitors by Market Cap
The table below lists competitors of Cognetivity Neurosciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
We Can Medicines Co., Ltd.
TWO:6929
|
$8.96K |
|
Future Generation Global Ltd
AU:FGG
|
$8.98K |
|
SCIENT DIGIT IMAG
BE:SD0
|
$8.98K |
|
Pengana Private Equity Trust
AU:PE1
|
$8.99K |
|
Fine Besteel Co. Ltd.
KQ:133820
|
$8.95K |
|
BioLASCO Taiwan Co., Ltd.
TWO:6662
|
$8.95K |
|
MATD3F
SA:MATD3F
|
$8.95K |
|
Watkin Jones PLC
LSE:WJG
|
$8.93K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cognetivity Neurosciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -5,675,378 to -9,889,538, a change of -4,214,160.
- Net loss of 7,433,815 reduced equity.
- New share issuances of 6,879,270 increased equity.
- Other comprehensive income increased equity by 427,485.
- Other factors decreased equity by 4,087,100.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.43 Million | -75.17% |
| Share Issuances | $6.88 Million | +69.56% |
| Other Comprehensive Income | $427.49K | +4.32% |
| Other Changes | $-4.09 Million | -41.33% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cognetivity Neurosciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-01-31 | $0.00 | $0.00 | x |
| 2017-01-31 | $0.00 | $0.00 | x |
| 2018-01-31 | $0.08 | $0.00 | x |
| 2019-01-31 | $0.01 | $0.00 | x |
| 2020-01-31 | $-0.01 | $0.00 | x |
| 2021-01-31 | $0.01 | $0.00 | x |
| 2022-01-31 | $-0.08 | $0.00 | x |
| 2023-01-31 | $-0.12 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cognetivity Neurosciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16386.31%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-142.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-56.40K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-448.90K |
| 2018 | -44.15% | 0.00% | 0.00x | 1.11x | $-1.83 Million |
| 2019 | -874.54% | 0.00% | 0.00x | 1.49x | $-4.24 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.62 Million |
| 2021 | -223.44% | 0.00% | 0.00x | 2.12x | $-2.01 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.56 Million |
| 2023 | 0.00% | -16386.31% | 0.02x | 0.00x | $-6.44 Million |
Industry Comparison
This section compares Cognetivity Neurosciences Ltd's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $79,108,599
- Average return on equity (ROE) among peers: -247.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cognetivity Neurosciences Ltd (CGNSF) | $-15.20 Million | 0.00% | N/A | $8.96K |
| Accolade, Inc. (ACCD) | $473.79 Million | -97.02% | 0.91x | $448.32 Million |
| Achiko AG (ACHKF) | $-4.58 Million | 0.00% | 0.00x | $314.42K |
| Ascom Holding AG (ACMLF) | $78.70 Million | 22.11% | 1.51x | $152.13 Million |
| Accelera Innovations Inc (ACNV) | $-462.52K | 0.00% | 0.00x | $5.72K |
| Aclarion Inc (ACON) | $-7.08 Million | 0.00% | 0.00x | $1.89 Million |
| Alternate Health Corp (AHGIF) | $1.07 Million | -2231.82% | 7.94x | $6.50K |
| AI/ML Innovations Inc (AIMLF) | $2.09 Million | -130.52% | 0.72x | $6.84 Million |
| NetraMark Holdings Inc. (AINMF) | $-198.56K | 0.00% | 0.00x | $70.13 Million |
| AMJ Global Technology (AMJT) | $-21.78K | 0.00% | 0.00x | $10.99 Million |
| American Well Corp (AMWL) | $247.79 Million | -38.62% | 0.31x | $78.62 Million |